[18F]-C-SNAT4:改进的caspase-3敏感纳米聚集PET示踪剂用于肿瘤化疗和免疫治疗反应成像
本研究设计合成改进的18F标记caspase敏感纳米聚集示踪剂[18F]-C-SNAT4,在体外用顺铂处理敏感和耐药NSCLC细胞系,在小鼠肿瘤模型中评估化疗和免疫治疗反应。结果显示[18F]-C-SNAT4摄取与肿瘤凋亡水平和疗效正相关,可监测两种治疗模式的反应并预测疗效。
要点
- [18F]-C-SNAT4在NCI-H460细胞中摄取呈时间和剂量依赖性升高,与细胞死亡相关。
- 耐药NCI-H1299细胞及肿瘤异种移植中[18F]-C-SNAT4快速清除。
- 在CT26荷瘤小鼠中可区分免疫检查点抑制剂治疗应答与无应答。
核心结论
- [18F]-C-SNAT4在化疗和免疫治疗肿瘤中的摄取与肿瘤凋亡水平和疗效正相关。
- [18F]-C-SNAT4 PET可在临床前小鼠模型中监测肿瘤对两种治疗模式的反应并预测疗效。
研究设计与样本
- 临床前小鼠模型研究,合理设计并合成新型PET示踪剂[18F]-C-SNAT4。
- 体外摄取研究使用顺铂不同剂量处理的药物敏感NCI-H460和耐药NCI-H1299 NSCLC细胞系。
- 体内治疗反应监测评估化疗和免疫治疗两种模式,使用两种小鼠肿瘤异种移植模型。
- 肿瘤示踪剂摄取用γ计数和cleaved caspase-3免疫荧光进行离体验证。
主要发现
- [18F]-C-SNAT4合成简便且血清稳定性改善。
- [18F]-C-SNAT4在NCI-H460细胞中摄取呈时间和剂量依赖性升高,与细胞死亡相关良好。
- NCI-H460肿瘤异种移植小鼠中[18F]-C-SNAT4摄取显著增加。
- 耐药NCI-H1299体外和肿瘤异种移植中[18F]-C-SNAT4快速清除。
- 在接受检查点抑制剂的BALB/C小鼠CT26结肠癌异种移植中,[18F]-C-SNAT4可监测免疫治疗诱导的凋亡并区分治疗应答与无应答小鼠。
临床怎么用
- 临床前证据提示[18F]-C-SNAT4 PET可用于无创监测肿瘤化疗和免疫治疗后的凋亡反应。
- 耐药肿瘤中示踪剂快速清除,可能有助于识别治疗无应答。
局限性
- 研究仅在临床前小鼠模型中进行,尚未在患者中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Positron emission tomography (PET) imaging of apoptosis can noninvasively detect cell death in vivo and assist in monitoring tumor response to treatment in patients. While extensive efforts have been devoted to addressing this important need, no apoptosis PET imaging agents have yet been approved for clinical use. This study reports an improved 18F-labeled caspase-sensitive nanoaggregation tracer ([18F]-C-SNAT4) for PET imaging of tumor response to chemo- and immunotherapies in preclinical mouse models. METHODS: We rationally designed and synthesized a new PET tracer [18F]-C-SNAT4 to detect cell death both in vitro and in vivo. In vitro radiotracer uptake studies were performed on drug-sensitive and -resistant NSCLC cell lines (NCI-H460 and NCI-H1299, respectively) treated with cisplatin at different doses. In vivo therapy response monitoring by [18F]-C-SNAT4 PET imaging was evaluated with two treatment modalities-chemotherapy and immunotherapy in two tumor xenografts in mice. Radiotracer uptake in the tumors was validated ex vivo using γ-counting and cleaved caspase-3 immunofluorescence. RESULTS: This [18F]-C-SNAT4 PET tracer was facilely synthesized and displayed improved serum stability profiles. [18F]-C-SNAT4 cellular update was elevated in NCI-H460 cells in a time- and dose-dependent manner, which correlated well with cell death. A significant increase in [18F]-C-SNAT4 uptake was measured in NCI-H460 tumor xenografts in mice. In contrast, a rapid clearance of [18F]-C-SNAT4 was observed in drug-resistant NCI-H1299 in vitro and in tumor xenografts. Moreover, in BALB/C mice bearing murine colon cancer CT26 tumor xenografts receiving checkpoint inhibitors, [18F]-C-SNAT4 showed its ability for monitoring immunotherapy-induced apoptosis and reporting treatment-responding mice from non-responding. CONCLUSION: The uptake of [18F]-C-SNAT4 in tumors received chemotherapy and immunotherapy is positively correlated with the tumor apoptotic level and the treatment efficacy. [18F]-C-SNAT4 PET imaging can monitor tumor response to two different treatment modalities and predict the therapeutic efficacy in preclinical mouse models.
引用
- Chen M, Chen Z, Castillo JB, et al. [18F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies. Eur J Nucl Med Mol Imaging. 2021. PMID: 33712870. doi:10.1007/s00259-021-05297-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。